

Hilary M Dubrock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1633974/publications.pdf>

Version: 2024-02-01

44
papers

908
citations

643344

15
h-index

536525

29
g-index

45
all docs

45
docs citations

45
times ranked

1080
citing authors

#	ARTICLE	IF	CITATIONS
1	Histologic and proteomic remodeling of the pulmonary veins and arteries in a porcine model of chronic pulmonary venous hypertension. <i>Cardiovascular Research</i> , 2023, 119, 268-282.	1.8	4
2	ICU and Hospital Outcomes in Patients with Hepatopulmonary Syndrome Undergoing Liver Transplantation. <i>Lung</i> , 2022, 200, 5.	1.4	5
3	Mending the Model for End-Stage Liver Disease: An in-depth review of the past, present, and future portopulmonary hypertension Model for End-Stage Liver Disease exception. <i>Liver Transplantation</i> , 2022, 28, 1224-1230.	1.3	7
4	Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications. <i>European Heart Journal</i> , 2022, 43, 3417-3431.	1.0	50
5	Palliative Care and Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2022, 21, 7-11.	0.1	1
6	CAQ Corner: Cardiovascular and pulmonary evaluation of liver transplantation candidates: What you need to know for the board exam. <i>Liver Transplantation</i> , 2022, 28, 1530-1539.	1.3	1
7	Prevalence of pulmonary hypertension in adults after atrial switch and role of ventricular filling pressures. <i>Heart</i> , 2021, 107, 468-473.	1.2	6
8	Healthcare Utilization and Costs associated with Hereditary Hemorrhagic Telangiectasia Patients in a Large US Claims Database. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 55-64.	1.2	0
9	Sex Differences in Portopulmonary Hypertension. <i>Chest</i> , 2021, 159, 328-336.	0.4	7
10	Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life. <i>Pulmonary Circulation</i> , 2021, 11, 1-9.	0.8	8
11	Use of Remdesivir in Myasthenia gravis and COVID-19. <i>Pharmacotherapy</i> , 2021, 41, 546-550.	1.2	5
12	Impact of Right Ventricular Dysfunction on Short-term and Long-term Mortality in Sepsis. <i>Chest</i> , 2021, 159, 2254-2263.	0.4	33
13	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. <i>Pulmonary Circulation</i> , 2021, 11, 1-10.	0.8	17
14	Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1266-1274.	5.2	62
15	Topic-Based, Recent Literature Review on Pulmonary Hypertension. <i>Mayo Clinic Proceedings</i> , 2021, 96, 3109-3121.	1.4	6
16	Outcomes of liver transplantation in patients with hepatopulmonary syndrome in the pre and post-MELD eras: A systematic review. <i>Respiratory Medicine and Research</i> , 2021, 80, 100852.	0.4	5
17	Clinical Outcomes After Liver Transplantation in Patients With Portopulmonary Hypertension. <i>Transplantation</i> , 2021, 105, 2283-2290.	0.5	24
18	Hepatopulmonary Syndrome and Portopulmonary Hypertension: Pulmonary Vascular Complications of Liver Disease. , 2021, 11, 3281-3302.		6

#	ARTICLE	IF	CITATIONS
19	Outcomes After Noncardiac Surgery for Patients with Pulmonary Hypertension: A Historical Cohort Study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, 1506-1513.	0.6	20
20	Hemodynamics in Adults With the Shone Complex. <i>American Journal of Cardiology</i> , 2020, 130, 137-142.	0.7	12
21	Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia-Related Bleeding and High-Output Cardiac Failure. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1604-1612.	1.4	11
22	Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2020, 158, 2568-2578.	0.4	20
23	Prevalence and Impact of Restrictive Lung Disease in Liver Transplant Candidates. <i>Liver Transplantation</i> , 2020, 26, 989-999.	1.3	5
24	The Myths and Realities of Portopulmonary Hypertension. <i>Hepatology</i> , 2020, 72, 1455-1460.	3.6	14
25	Outcomes of Liver Transplantation in Treated Portopulmonary Hypertension Patients With a Mean Pulmonary Arterial Pressure ≥ 35 mmHg. <i>Transplantation Direct</i> , 2020, 6, e630.	0.8	20
26	CHYLOPERICARDIUM SECONDARY TO THORACIC DUCT OBSTRUCTION IN A PATIENT WITH PLASTIC BRONCHITIS. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2264.	1.2	0
27	Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Initial Single-Center Experience. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 311-318.	1.2	29
28	Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes. <i>Transplantation Direct</i> , 2019, 5, e456.	0.8	17
29	Pulmonary Evaluation of Liver Transplant Candidates. , 2019, , 25-45.		0
30	Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding. <i>Mayo Clinic Proceedings</i> , 2018, 93, 155-166.	1.4	88
31	Clinical Impact of Intrapulmonary Vascular Dilatation in Candidates for Liver Transplant. <i>Chest</i> , 2018, 153, 414-426.	0.4	16
32	Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. <i>Circulation</i> , 2018, 137, 1796-1810.	1.6	223
33	INOTROPES FOR RIGHT VENTRICULAR FAILURE IN PULMONARY ARTERIAL HYPERTENSION. <i>Chest</i> , 2018, 154, 1038A.	0.4	1
34	High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. <i>PLoS ONE</i> , 2018, 13, e0201836.	1.1	78
35	Predictors of Waitlist Mortality in Portopulmonary Hypertension. <i>Transplantation</i> , 2017, 101, 1609-1615.	0.5	56
36	Do Late Bubbles Correspond to Early Hepatopulmonary Syndrome?. <i>Annals of Hepatology</i> , 2017, 16, 476-477.	0.6	0

#	ARTICLE	IF	CITATIONS
37	ATS Core Curriculum 2016. Part IV. Adult Pulmonary Medicine Core Curriculum. Annals of the American Thoracic Society, 2016, 13, 1160-1169.	1.5	1
38	Macrophage Migration Inhibitory Factor as a Novel Biomarker of Portopulmonary Hypertension. Pulmonary Circulation, 2016, 6, 498-507.	0.8	15
39	Pulmonary Capillary Hemangiomas: The Role of Invasive Cardiopulmonary Exercise Testing. Pulmonary Circulation, 2015, 5, 580-586.	0.8	5
40	Pulmonary Vessel Cross-sectional Area before and after Liver Transplantation. Academic Radiology, 2015, 22, 752-759.	1.3	0
41	What's new in the treatment of portopulmonary hypertension?. Expert Review of Gastroenterology and Hepatology, 2015, 9, 983-992.	1.4	22
42	ATS Core Curriculum 2015. Part I: Adult Pulmonary Medicine. Annals of the American Thoracic Society, 2015, 12, 1387-1397.	1.5	2
43	Macitentan for the treatment of pulmonary arterial hypertension. Expert Review of Respiratory Medicine, 2014, 8, 393-399.	1.0	3
44	Palpitations, Hypotension, Hypokalemia, and Hyperlactatemia. Putting the Pieces Together. Annals of the American Thoracic Society, 2014, 11, 1319-1322.	1.5	2